ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CLDN Eiger Biopharmaceuticals Com

1.15
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Eiger Biopharmaceuticals Com NASDAQ:CLDN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.15 0 01:00:00

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corp. of Pendency of Class Action Lawsuit & a Lead...

17/08/2015 7:51pm

Business Wire


CELLADON CORP (NASDAQ:CLDN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more CELLADON CORP Charts.

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Celladon Corporation (“Celladon”) (NASDAQGM:CLDN) between July 7, 2014 and June 25, 2015.

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California. If you purchased or otherwise acquired Celladon Corporation securities between July 7, 2014 and June 25, 2015, your rights may be affected by this action. To get more information go to:

http://zlk.9nl.com/celladon-cldn

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or failed to disclose adverse information regarding the Company’s prospects for its lead drug candidate, MYDICAR, for treating enzyme deficiency in heart failure patients that results in inadequate pumping of the heart.

On April 26, 2015, Celladon announced that the Company’s Phase 2b CUPID2 trial of MYDICAR did not meet its primary and secondary goals. Then on June 1, 2015, Celladon issued a press release announcing the abrupt resignation of the Company’s Chief Executive Officer. Then, on June 26, 2015, Celladon announced the suspension of its plans for further research or development of its MYDICAR program and other pre-clinical programs, indicating there was a possibility that the Company could be liquidated with net cash available to shareholders of $25-$30 million.

If you suffered a loss in Celladon you have until August 31, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLPJoseph E. Levi, Esq., 212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com

1 Year CELLADON CORP Chart

1 Year CELLADON CORP Chart

1 Month CELLADON CORP Chart

1 Month CELLADON CORP Chart

Your Recent History

Delayed Upgrade Clock